Role of RANKL inhibition in osteoporosis

ar2167 ARJ Review Role of RANKL inhibition in osteoporosis McClung Michael mmcclung@orost.com

Oregon Osteoporosis Center, NE Hoyt Street, Portland, Oregon 97213, USA

Arthritis Research & Therapy Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor Edward M Schwarz and Christopher T Ritchlin Supported by an unrestricted grant from Amgen Inc. Reviews 1478-6354 2007 9 Suppl 1 S3 http://arthritis-research.com/content/9/S1/S3 17634142 10.1186/ar2167 29 6 2007 2007 BioMed Central Ltd

Abstract

When the rate of bone resorption exceeds that of bone formation, destruction of bone tissue occurs, resulting in a fragile skeleton. The clinical consequences, namely osteoporosis and fragility fractures, are common and costly problems. Treatments that normalize the balance of bone turnover by inhibiting bone resorption preserve bone mass and reduce fracture risk. The discovery of receptor activator of nuclear factor-κB ligand (RANKL) as a pivotal regulator of osteoclast activity provides a new therapeutic target. Early studies have demonstrated that denosumab, an investigational, highly specific anti-RANKL antibody, rapidly and substantially reduces bone resorption. Pharmacokinetics of the antibody allow dosing by subcutaneous injection at an interval of 6 months. Inhibiting RANKL appears to be a promising new treatment for osteoporosis and related disorders. More information about the effectiveness of denosumab in reducing fracture risk, its tolerability and safety, and the response to discontinuing therapy will be provided by ongoing clinical studies.

Introduction

Osteoporosis is a disorder of impaired bone strength that results in skeletal fragility and increased fracture risk 1. It is a common and costly disorder, and is associated with significant morbidity and mortality 2. About 10 million American adults have osteoporosis, and a further 34 million have low bone density, many of whom are at increased risk for fracture 3. More than 1.5 million osteoporotic fractures occur in the USA each year. This results in more than half a million hospitalizations, more than 800,000 emergency room encounters, more than 2,600,000 physician office visits, and the placement of nearly 180,000 individuals in nursing homes.

Painful vertebral fractures are the most common complication of osteoporosis, accounting for about half of fractures. Height loss, kyphosis, back pain, and impaired physical and psychological function occur following such fractures 4. Having a spine fracture is the strongest risk factor for having another fracture of either hip or spine 5. Hip fractures are the most devastating type of fracture, accounting for about 300,000 hospitalizations each year and an excess mortality of about 20% 3. One-third of hip fractures occur in men. A healthy 50-year-old woman has a 40% to 50% chance of experiencing an osteoporosis-related fracture over the remainder of her lifetime, whereas approximately 20% of men will experience fragility fractures.

Caring for patients with these fractures is expensive; the annual direct care expenditure on caring for patients with osteoporotic fractures was US$12 to 18 billion in 2002 3. The incidence of fractures increases progressively with advancing age. Furthermore, as the global population grows older, the number of fractures is expected to double or triple by the year 2050, resulting in increased costs both to individuals and to society 6.

Pathophysiology of bone loss and fractures

Bone mass accumulates during the first two decades of life. In healthy persons, peak bone mass is influenced primarily by genetic factors and body size 7. Illnesses or nutritional deficiency during childhood and reduced exposure to sex steroids during adolescence often blunt the acquisition of peak bone mass, predisposing to osteoporosis in later life.

After the completion of skeletal growth, bone health is maintained by the coupled processes of bone resorption and bone formation, together called bone remodeling 8. Old or damaged bone is removed and replaced by healthy bone. In young adults these processes are balanced, and skeletal renewal occurs without significant change in bone mass. Various diseases, drugs, and metabolic abnormalities adversely affect bone health and contribute to the development of osteoporosis. Activation of osteoclastic bone resorption is a common factor in the pathogenesis of bone loss and fractures 9. Estrogen deficiency at menopause or androgen deficiency in men results in an unbalanced increase in bone turnover, such that bone resorption exceeds bone formation. Relatively rapid bone loss occurs and is accompanied by destruction of bone microarchitecture 10. In older adults vitamin D deficiency is common; it impairs calcium absorption and induces secondary hyperparathyroidism, in turn resulting in bone loss and increased fracture risk 11.

Low bone mineral density (BMD) is an important risk factor for fractures. For every standard deviation decrease in age-adjusted BMD, the relative risk for fracture increases by 1.5-fold to 2.5-fold 12. The relationship between BMD and fracture risk is strongly modulated by age and other clinical risk factors such as prior fracture history, lifestyle factors, and frailty 13. Estimates of fracture probability, made by combining bone density and clinical risk factors, can be used to identify patients for whom therapy would be appropriate.

Treatment of osteoporosis

The primary objective of treating patients with or who are at risk for osteoporosis is to reduce the likelihood of new fractures, and effective therapies exist. The use of calcium and vitamin D supplements in older adults and hip protectors in fall-prone elderly patients have been shown to reduce fracture risk 1415. However, bone-strengthening osteoporosis drugs are the most effective therapies. The anti-resorptive (anticatabolic) drugs estrogen, raloxifene, and bisphosphonates effectively prevent bone loss in post-menopausal women without osteoporosis 161718. Treatment with either an antiresorptive drug or teriparatide, an anabolic agent, preserves or improves bone mass and substantially reduces fracture risk in postmenopausal women and men with osteoporosis 19. In the clinical trial setting, bisphosphonates, raloxifene, and teriparatide reduced the incidence of new vertebral fractures by about 50% and the incidence of multiple spine fractures by 75% to 95% 20212223. Bisphosphonates and teriparatide reduce the incidence of non-vertebral fracture, and both alendronate and risedronate decrease the incidence of hip fracture in postmenopausal women with osteoporosis by about 50% 2024. The potential to achieve additive effects by combining a potent antiresorptive agent such as alendronate with a bone-forming drug such as teriparatide has not yet been realized 2526. The anabolic effects of teriparatide, assessed by changes in bone density, biochemical indices of bone turnover, and bone histomorphometry, were blunted when the agent was administered concurrently with alendronate.

In general these therapies are well tolerated. The effectiveness of treatment in clinical practice is limited by real or perceived intolerance, and especially by poor adherence to therapy, because most patients discontinue treatment before the end of the first year 2728.

Rationale for RANKL inhibitors to treat osteoporosis

Receptor activator of nuclear factor-κB (RANK) is a member of the tumor necrosis factor family expressed by osteoclasts and their precursors 29. The interaction of RANK with its ligand (RANKL) has been identified as the final common pathway through which bone resorption is regulated 29. By binding to its receptor RANK on osteoclastic precursors, RANKL controls the differentiation, proliferation, and survival of osteoclasts. Osteoprotegerin (OPG) is the natural inhibitor of RANKL. Mice that are deficient in OPG exhibit osteoporosis, whereas over-expression of OPG in mice results in reduced numbers of osteoclasts and high bone mass 3031. Perturbations in the ratio of OPG to RANKL have been demonstrated to occur with estrogen deficiency, hyperparathyroidism, and other disorders that stimulate bone resorption 323334. RANKL is also expressed by lymphocytes and synovial fibroblasts and may mediate bone loss associated with inflammatory conditions 3536. The discovery of the RANK/RANKL/OPG pathway and its implications in the pathogenesis of osteoporosis provides a molecular target for new therapies to improve bone health. RANK and RANKL are expressed by endothelial cells and lymphocytes, and this pathway may have importance in cardiovascular diseases and immune function 37.

Preclinical studies

Studies in animals have evaluated the effects of administering recombinant OPG or OPG fused to immunoglobulin Fc fragments (to increase the half-life of OPG). The osteopenia observed in OPG-deficient mice was reversed by injections of the OPG-Fc fusion protein or by introducing the OPG gene using an adenovirus expression vector 3839. Post-oophorectomy bone loss in rats was prevented or reversed by administration of OPG-Fc fusion protein 4041. This treatment quickly and potently inhibited indices of bone resorption, and was associated with normal bone histology and significant improvement in bone strength. OPG therapy prevented bone loss in immobilized rats 42.

A preliminary report by Kostenuik and his colleagues, presented at the European Congress on Clinical and Economic Aspects of Osteoporosis in 2005 43, described the effects of treating intact female cynomologous monkeys with OPG-Fc for 6 months. Urinary N-telopeptide (NTX), a marker of bone resorption, was reduced by about 90%. This was accompanied by improvements in bone mass in both the trabecular and cortical compartments of the distal radius and proximal tibia, as measured by peripheral quantitative computed tomography. Cortical bone mineral content increased, as compared with the control group, by 269% in the distal radius and 67% in the proximal tibia with OPG therapy. Cortical thickness increased by 251% and 39% in the radius and tibia, respectively. This increase in cortical thickness was the result of both a decrease in the resorption of the inner surface of the cortex (decreased endosteal circumference of 40% with treatment) and either enhanced deposition or decreased resorption of bone on the outer surface (increased periosteal circumference of 20%). As a result of both the increase in bone mineral content and the increase in cortical thickness and diameter, a calculated index of bone strength was increased by 288% in treated compared with control animals. These effects on cortical bone structure are substantially greater than have been observed with other antiresorptive agents.

At the 2006 Meeting of the American Society for Bone and Mineral Research, the same group reported the effects of inhibiting RANKL with an anti-RANKL antibody in estrogen-deficient older monkeys 44. Therapy for up to 16 months prevented loss of cancellous bone and preserved indices of bone strength. Combining OPG therapy with parathyroid hormone resulted in greater increases in BMD and bone strength in rats than was achieved with either treatment alone 4546.

Clinical experience with RANKL inhibitors

Osteoprotegerin

To evaluate the concept that inhibition of RANKL could have clinical utility, 52 healthy postmenopausal women were given single doses of Fc:OPG of 0.1. 0.3, 1.0, and 3.0 mg/kg in a phase I, randomized, placebo-controlled study 47. The women were followed for 84 days to determine the effects of OPG therapy on urinary NTX (a specific marker of bone resorption) and bone-specific alkaline phosphatase (BSAP; an index of bone formation). Within 12 hours, a dose-dependent decrease in NTX/creatinine ratio was observed. Decreases of 70% to 80% occurred within 5 days with the highest doses. NTX/creatinine values returned to baseline within several weeks. Significant decreases in BSAP levels were observed with the two higher doses. Inhibition of BSAP occurred more slowly, reaching a nadir at 60 days in the 3.0 mg/kg group of about 30% below baseline. No serious or severe adverse events were reported. A transient neutralizing antibody to OPG was observed in one patient, without obvious clinical effects.

These data provide evidence that inhibition of RANKL, in this case by its natural inhibitor OPG, can have clinically measurable effects. However, the development of OPG as a therapy for osteoporosis was not pursued because of its potential immunogenicity, because immunologic resistance to OPG could have substantial untoward effects on the skeleton.

Anti-RANKL antibody

Denosumab (formerly called AMG 162) is a fully human IgG₂monoclonal antibody that binds with high affinity to human RANKL and blocks binding of RANKL to RANK 48. Compared with OPG, denosumab binds RANKL more specifically (it is less likely to affect the immune and other regulatory systems), it does not have the potential for autoimmunization against a vital regulatory protein, and it has a longer half-life, which permits less frequent dosing 48. Each of these attributes makes denosumab a more attractive therapeutic agent than forms of OPG.

Single doses of denosumab ranging from 0.01 to 3.0 mg/kg were administered by subcutaneous injection to 49 healthy postmenopausal women in a phase I study conducted to evaluate safety, pharmacokinetics, and effects on bone resorption 48. Pharmacokinetics were nonlinear with dose. A prolonged absorption phase occurred, with maximum serum concentrations being reached between 5 and 21 days after dosing. Disappearance from serum occurred in two phases: a slow phase with half-life ranging from about 20 days at lower doses to about 32 days at higher doses. Below circulating levels of about 1,000 ng/ml, denosumab disappeared more rapidly. Urinary NTX levels were reduced within 12 hours of dosing. The magnitude of the initial response differed only modestly among the doses, but the duration of the effect was dose related, as predicted from the pharmacokinetic data. With a dose of 1 mg/kg (approximately 60 mg in an average size woman), inhibition of bone resorption was sustained for at least 6 months. A return of NTX levels toward baseline was observed with all of the doses by the end of the 9-month follow-up period. Serum levels of BSAP remained stable for the first 2 weeks and then decreased in a dose-dependent manner, suggesting that the effect on bone formation is an indirect effect. The drug appeared to be well tolerated, with two mild injection site reactions reported. No changes were noted in circulating numbers of white blood cells, T or B lymphocytes, immuno-globulins, or coagulation factors.

Encouraged by these results, 412 postmenopausal women with low BMD were enrolled in a phase II, randomized, double-blind, placebo-controlled, dose-ranging trial conducted to determine the effect of denosumab on lumbar spine BMD 49. The women received subcutaneous injections of placebo or denosumab doses of 6, 14, or 30 mg every 3 months, or 14, 60, 100, or 210 mg every 6 months. A separate group was randomly assigned to receive open-label oral alendronate 70 mg once weekly. Treatment groups included 41 to 54 women. All women received calcium 1000 mg and vitamin D 400 IU daily. The study was planned to last for 2 years, with the primary analysis scheduled after 12 months.

After 12 months, BMD in the lumbar spine, measured by dual-energy X-ray absorptiometry, increased similarly in all treatment groups except for the group receiving the smallest 6-monthly dose of denosumab (14 mg) 49. The average increase was 4.6% in women who received denosumab 60 mg every 6 months or alendronate, as compared with a decrease of 0.8% in the placebo group (P < 0.0001 versus placebo; Figure 1). BMD responses in regions of the proximal femur and total body were at least as great with all but the lowest dose of denosumab compared with alendronate. In the distal radius, a modest increase in BMD occurred with denosumab at 60 mg every 6 months (1.3%), whereas values decreased by 0.5% with alendronate and by 2% in the placebo group (Figure 1).

Figure 1

Changes in bone mineral density with denosumab, alendronate, and placebo

Changes in bone mineral density with denosumab, alendronate, and placebo. Shown here are mean percentage changes from baseline at 12 months in bone mineral density at the lumbar spine, total hip region, and distal third of the radius in women who received placebo (open bars), denosumab 60 mg every 6 months (solid bars), and alendronate 70 mg once weekly (stippled bars) [46]. *P < 0.001 versus placebo; **P < 0.05 versus placebo; ^‡nominal P < 0.01 versus alendronate. SE, standard error.

Biochemical indices of bone resorption (serum C-telopeptide [CTX] and urinary NTX) and bone formation (BSAP) were measured at 3 days and at monthly intervals after the initial dose 49. At 3 days, median levels of serum CTX were reduced by 68% to 83%, and urinary NTX fell by 48% to 61% from baseline values in the denosumab treatment groups. Resorption marker values approached or had reached their nadir at 1 month. At this time, CTX values had decreased from baseline by 85% to 88% with all doses of denosumab, by 62% with alendronate, and by 4% in the placebo group. No differences were noted in initial response between denosumab doses, but the duration of inhibition of bone resorption was dose dependent; larger doses induced longer responses than did smaller doses. At least partial reversal of inhibition of bone resorption was observed with all but the largest dose of denosumab before the second doses were administered at 3 or 6 months. Similar responses of bone resorption markers were observed with subsequent dosing. Serum BSAP levels did not change during the first month after dosing, and then gradually decreased in all treatment groups to about 60% below baseline values. No differences were observed in the magnitude or timing of BSAP responses among the groups receiving denosumab and that receiving alendronate.

A transient decrease in serum calcium and a concomitant rise in serum parathyroid hormone typically occurs within the first few weeks after administration of a potent anti-resorptive agent. This was observed both in the groups receiving denosumab and in those receiving alendronate 49. In six women who received denosumab (1.9%), the albumin-adjusted serum calcium value fell below the reference range. None of the women experienced symptoms of hypocalcemia, and values spontaneously returned to the normal range.

Denosumab was well tolerated 49. The frequency of adverse experiences was similar among all treatment groups, and there was no evidence of a dose-response effect of denosumab for any set of adverse experiences. Two mild and transient injection site reactions occurred. Because RANKL is expressed in lymphocytes, special attention was given to evaluation of immune function. No clinical or laboratory evidence of an adverse effect on the immune system was noted. Two women developed transient non-neutralizing anti-denosumab antibodies. In neither woman did the antibody appear to alter therapeutic effectiveness. Unlike the potential for skeletal harm with anti-OPG antibodies, immunologic resistance to denosumab would not adversely affect the skeleton but would simply render the drug ineffective.

Preliminary results of the second year of this study were presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis in March 2006 50. Therapeutic effectiveness persisted. Increases in BMD were maintained or improved. The patterns of inhibition of bone resorption markers following doses administered during the second year were identical to those observed during the first year. No tolerability or safety concerns were identified during the second year.

Extensions of the phase II study will evaluate safety for longer treatment periods and will provide information about the extent of reversibility following discontinuation of treatment. Doses of 30 mg every 3 months and 60 mg every 6 months appeared be the best suited for clinical use. Because of the potential to improve long-term adherence to therapy with less frequent dosing, 60 mg every 6 months has been selected for further development for the treatment of osteoporosis. Phase III studies are underway to evaluate the effectiveness of denosumab in reducing fracture risk in postmenopausal women with osteoporosis and in preventing bone loss in women without osteoporosis. These studies are substantially larger than the phase II study and will provide much more information about the safety and tolerability of denosumab. Additional studies will determine the effectiveness of denosumab in treating patients with osteoporosis induced by drug treatment, including glucocorticoid therapy, aromatase inhibitors (in women with breast cancer), and inhibitors of gonadotropin secretion (in men with prostate cancer).

Conclusion

Inhibiting RANKL with a highly specific antibody significantly affects bone metabolism and appears to be a promising treatment for osteoporosis and other bone diseases characterized by increased bone turnover. In addition to documenting and quantifying the efficacy of denosumab therapy in large numbers of patients, it will be important to monitor potential effects on the cardiovascular and immune systems.

Abbreviations

BMD = bone mineral density; BSAP = bone-specific alkaline phosphatase; CTX = C-telopeptide; NTX = N-telopeptide; OPG = osteoprotegerin; RANK = receptor activator of nuclear factor-κB; RANKL = receptor activator of nuclear factor-κB ligand.

Competing interests

MM receives research grants and consulting fees from Amgen, Lilly, Merck, Novartis, Procter & Gamble, Roche, and Sanofi-Aventis.

Acknowledgements

I thank Ms Joyce Allnutt for secretarial and editorial assistance.

This article is published as part of Arthritis Research & Therapy Volume 9 Supplement 1, 2007: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor. The full contents of the supplement are available online at http://arthritis-research.com/supplements/9/S1.

Publication of the supplement has been supported by an unrestricted grant from Amgen Inc.

Osteoporosis prevention, diagnosis, and therapy NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy JAMA 2001 285 785 795 10.1001/jama.285.6.785 11176917 Mortality after osteoporotic fractures Johnell O Kanis JA Oden A Sernbo I Redlund-Johnell I Petterson C De Laet C Jonsson B Osteoporos Int 2004 15 38 42 10.1007/s00198-003-1490-4 14593451 US Department of Health and Human Services Bone Health and Osteoporosis: A Report of the Surgeon General Washington, DC: Public Health Service, Office of the Surgeon General 2004 The clinical consequences of vertebral compression fracture Silverman SL Bone 1992 Suppl 2 S21 S31 Fracture risk following an osteoporotic fracture Johnell O Kanis JA Oden A Sernbo I Redlund-Johnell I Petterson C De Laet C Jonsson B Osteoporos Int 2004 15 175 179 10.1007/s00198-003-1514-0 14691617 World-wide projections for hip fracture Gullberg B Johnell O Kanis JA Osteoporos Int 1997 7 407 413 10.1007/PL00004148 9425497 Peak bone mass Heaney RP Abrams S Dawson-Hughes B Looker A Marcus R Matkovic V Weaver C Osteoporos Int 2000 11 985 1009 10.1007/s001980070020 11256898 Pathogenesis of osteoporosis: concepts, conflicts, and prospects Raisz LG J Clin Invest 2005 115 3318 3325 1297264 16322775 10.1172/JCI27071 Risk factors for hip fracture in women with high BMD: EPIDOS study Robbins JA Schott AM Garnero P Delmas PD Hans D Meunier PJ Osteoporos Int 2005 16 149 154 10.1007/s00198-004-1661-y 15185066 Risedronate preserves bone architecture in early post-menopausal women in 1 year as measured by three-dimensional microcomputed tomography Dufresne TE Chmielewski PA Manhart MD Johnson TD Borah B Calcif Tissue Int 2003 73 423 432 10.1007/s00223-002-2104-4 12964065 Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications Lips P Endocr Rev 2001 22 477 501 10.1210/er.22.4.477 11493580 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures Marshall D Johnell O Wedel H BMJ 1996 312 1254 1259 2351094 8634613 Diagnosis of osteoporosis and assessment of fracture risk Kanis JA Lancet 2002 359 1929 1936 10.1016/S0140-6736(02)08761-5 12057569 Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials Bischoff-Ferrari HA Willett WC Wong JB Giovannucci E Diet-rich T Dawson-Hughes B JAMA 2005 293 2257 2264 10.1001/jama.293.18.2257 15886381 Prevention of hip fracture in elderly people with use of a hip protector Kannus P Parkkari J Niemi S Pasanen M Palvanen M Järvinen M Vuori I N Engl J Med 2000 343 1506 1513 10.1056/NEJM200011233432101 11087879 Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial The Writing Group for the PEPI JAMA 1996 276 1389 1396 10.1001/jama.276.17.1389 8892713 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women Delmas PD Bjarnason NH Mitlak BH Ravoux AC Shah AS Huster WJ Draper M Christiansen C N Engl J Med 1997 337 1641 1647 10.1056/NEJM199712043372301 9385122 Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort McClung MR Wasnich RD Hosking DJ Christiansen C Ravn P Wu M Mantz AM Yates J Ross PD Santora AC J Clin Endocrinol Metab 2004 89 4879 4885 10.1210/jc.2003-031672 15472179 Treatment of postmenopausal osteoporosis Delmas PD Lancet 2002 359 2018 2026 10.1016/S0140-6736(02)08827-X 12076571 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Black DM Cummings SR Karpf DB Cauley JA Thompson DE Nevitt MC Bauer DC Genant HK Haskell WL Marcus R Lancet 1996 348 1535 1541 10.1016/S0140-6736(96)07088-2 8950879 Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J JAMA 1999 282 637 645 10.1001/jama.282.7.637 10517716 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group Harris ST Watts NB Genant HK McKeever CD Hangartner T Keller M Chesnut CH III Brown J Eriksen EF Hoseyni MS JAMA 1999 282 1344 1352 10.1001/jama.282.14.1344 10527181 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis Neer RM Arnaud CD Zanchetta JR Prince R Gaich GA Reginster JY Hodsman AB Eriksen EF Ish-Shalom S Genant HK N Engl J Med 2001 344 1434 1441 10.1056/NEJM200105103441904 11346808 Effect of risedronate on the risk of hip fracture in elderly women McClung MR Geusens P Miller PD Zippel H Bensen WG Roux C Adami S Fogelman I Diamond T Eastell R N Engl J Med 2001 344 333 340 10.1056/NEJM200102013440503 11172164 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis Black DM Greenspan SL Ensrud KE Palermo L McGowan JA Lang TF Garnero P Bouxsein ML Bilezikian JP Rosen CJ N Engl J Med 2003 349 1207 1215 10.1056/NEJMoa031975 14500804 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis Finkelstein JS Hayes A Hunzelman JL Wyland JJ Lee H Neer RM N Engl J Med 2003 349 1216 1226 10.1056/NEJMoa035725 14500805 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Recker RR Gallagher R MacCosbe PE Mayo Clin Proc 2005 80 856 861 16007889 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Caro JJ Ishak KJ Huybrechts KF Raggio G Naujoks C Osteoporos Int 2004 15 1003 1008 10.1007/s00198-004-1652-z 15167989 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption Hofbauer LC Khosla S Dunstan CR Lacey DL Boyle WJ Riggs BL J Bone Miner Res 2000 15 2 12 10.1359/jbmr.2000.15.1.2 10646108 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Bucay N Sarosi I Dunstan CR Morony S Tarpley J Capparelli C Scully S Tan HL Xu W Lacey DL Gene Dev 1998 12 1260 1268 316769 9573043 10.1101/gad.12.9.1260 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett L Boone T Cell 1997 89 309 319 10.1016/S0092-8674(00)80209-3 9108485 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Hofbauer LC Khosla S Dunstan CR Lacey DL Spelsberg TC Riggs BL Endocrinology 1999 140 4367 4370 10.1210/en.140.9.4367 10465311 Mediators of the bisphasic responses of bone to intermittent and continuously administered parathyroid hormone Lochlin RM Khosla S Turner RT Riggs BL J Cell Biochem 2003 89 180 190 10.1002/jcb.10490 12682918 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells Hofbauer LC Gori F Riggs BL Lacey DL Dunstan CR Spelsberg TC Khosla S Endocrinology 1999 140 4382 4389 10.1210/en.140.10.4382 10499489 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through Osteoprotegerin ligand Kong YY Feige U Sarosi I Bolon B Tafuri A Morony Capparelli C Li J Elliott R McCabe S Wong T Nature 1999 402 304 309 10.1038/46303 10580503 Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis Takayanagi H Iizuka H Juji T Nakagawa T Yamamoto A Miyazaki T Koshihara Y Oda H Nakamura K Tanaka S Arthritis Rheum 2000 43 259 269 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W 10693864 Receptor activator of NF-kappa B and osteoprote-gerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis Collin-Osdoby P Rothe L Anderson F Nelson M Maloney W Osdoby P J Biol Chem 2001 276 20659 20672 10.1074/jbc.M010153200 11274143 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis Min H Morony S Sarosi I Dunstan CR Capparelli C Scully S Van G Kaufman S Kostenuik PJ Lacey DL J Exp Med 2000 192 463 474 10.1084/jem.192.4.463 10952716 2193236 Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis Bolon B Carter C Daris M Morony S Capparelli C Hsieh A Mao M Kostenuik P Dunstan CR Lacey DL Sheng JZ Mol Ther 2001 3 197 205 10.1006/mthe.2001.0245 11237676 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats Capparelli C Morony S Warmington K Adamu S Lacey D Dunstan CR Stouch B Martin S Kostenuik PJ J Bone Miner Res 2003 18 852 858 10.1359/jbmr.2003.18.5.852 12733724 Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function Shimizu-Ishiura M Kawana F Sasaki T J Electron Microsc 2002 51 315 325 10.1093/jmicro/51.5.315 Osteoprotegerin mitigates tail suspension-induced osteopenia Bateman TA Dunstan CR Ferguson VL Lacey DL Ayers RA Simske SJ Bone 2000 26 443 449 10.1016/S8756-3282(00)00256-8 10773583 The RANKL antagonist OPG-Fc causes significant increases in cortical bone thickness, density, and bone strength index in adult female cynomologus monkeys Kostenuik PJ Ominsky MS Cramner P Atkinson J Osteoporos Int 2005 Suppl 3 S68 AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys Atkinson J Cranmer P Saunders T Niehaus M Smith SY Varela A Ominsky MS Cosenza ME Kostenuik PJ J Bone Miner Res 2005 20 S29 OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Kostenuik PJ Capparelli C Morony S Adamu S Shimamoto G Shen V Lacey DL Dunstan CR Endocrinology 2001 142 4295 4304 10.1210/en.142.10.4295 11564687 Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats Valenta A Roschger P Fratzl-Zelman N Kostenuik PJ Dunstan CR Fratzl P Klaushofer K Bone 2005 37 87 95 10.1016/j.bone.2005.03.013 15869920 The effect of a single dose of osteoprotegerin in post-menopausal women Bekker PJ Holloway D Nakanishi A Arrighi M Leese PT Dunstan CR J Bone Miner Res 2001 16 348 360 10.1359/jbmr.2001.16.2.348 11204435 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women Bekker PJ Holloway DL Rasmussen AS Murphy R Martin SW Leese PT Holmes GB Dunstan CR DePaoli AM J Bone Miner Res 2004 19 1059 1066 10.1359/JBMR.040305 15176987 Denosumab in postmenopausal women with low bone mineral density McClung MR Lewiecki EM Cohen SB Bolognese MA Woodson GC Moffett AH Peacock M Miller PD Lederman SN Chesnut CH N Engl J Med 2006 354 821 831 10.1056/NEJMoa044459 16495394 Denosumab (AMG 162) inhibition of RANK ligand increases bone mineral density in postmenopausal osteoporosis women after two years of treatment Lewiecki EM Miller PD McClung MR Cohen SB Liu Y Wang A Fitzpatrick LA Osteoporos Int 2006 Suppl 2 S4